Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Staphylococcus aureus therapeutic phages
- Development stage
- Preclinical
- Lead developer
- Hospices Civils de Lyon
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraarticular, Intravenous, Parenteral
01
Overview
Anti-Staphylococcus aureus therapeutic phages are bacteriophages (viruses) specifically selected or engineered to target, infect, and lyse Staphylococcus aureus bacteria, including multidrug-resistant (MDR) strains such as methicillin-resistant S. aureus (MRSA). In the context of the French PHAG-ONE project, led by the Hospices Civils de Lyon (HCL) in collaboration with INSERM and CNRS, a public platform has been established to manufacture GMP-grade therapeutic phages. This program has developed a cocktail of four strictly virulent anti-S. aureus phages (including Silviavirus phages such as V1SA19, V1SA20, and V1SA22) that collectively cover approximately 88% of the genetic and clinical diversity of S. aureus. These phages are designed for intravenous and local administration to treat severe infections, such as bone and joint infections, and are being deployed for compassionate use and clinical trials.
- Other names
- anti-S. aureus phagesanti-Staphylococcus aureus bacteriophagesPHAG-ONEPHAGEinLYON
02
Targets
Staphylococcus aureus cytoplasmic membranePGN (Peptidoglycan)
Beyond the preview
Go deeper on anti-Staphylococcus aureus therapeutic phages.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Staphylococcus aureus therapeutic phages.